Emyria Limited (ASX:EMD)

Market Cap	44.16M
Revenue (ttm)	1.39M
Net Income (ttm)	-3.14M
Shares Out	669.15M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,054,320
Average Volume	3,101,885
Open	0.0650
Previous Close	0.0660
Day's Range	0.0640 - 0.0660
52-Week Range	0.0210 - 0.0780
Beta	0.20
RSI	51.93
Earnings Date	Aug 29, 2025

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.